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Authors' response
We agree with the observation that research fatigue could well lead to a bias of patients with more severe and death rattle being recruited in phase 2 (glycopyrrolate). However, as Murtagh and colleagues point out, this would probably lead to a reduction in the apparent efficacy of glycopyrrolate. Our results suggested that efficacy at 1 hour was not statistically different between hyoscine hydrobromide and glycopyrrolate. The interesting finding was that a significant difference existed at the 30-minute assessment. We were not claiming that glycopyrrolate was globally less effective than hyoscine, rather that a 200 mg glycopyrrolate injection may take longer to work than 400 mg hyoscine. This is supported by pharmacokinetic studies, which also suggest that this could be overcome by using a larger dose of glycopyrrolate.
With regard to the impact on prescribing of other drugs with sedative or antiemetic effect, we are interested to hear their findings. It is quite possible that the potential bias mentioned above would have unwittinglỳ selected' patients who required more sedation because they were more agitated; this could be an alternative explanation for the increased use of midazolam, diamorphine and levomepromazine we saw in phase 2. However, it is interesting that Murtagh et al. make (valid) criticism of the shortfalls of our methodology and weakness of our conclusions, but appear to want to believe the results of their study, which would appear to suffer the same weakness of methodology.
Hyoscine hydrobromide has been used to treat death rattle for many years. There has been little research done, but a wealth of experience. Most general practitioners, junior and senior hospital doctors are familiar with its use. It is unknown whether the sedative and antiemetic effects are beneficial additional effects, or unnecessary side-effects for most patients. Although glycopyrrolate is very well tried and tested in anaesthetic practice, its recent introduction for treating death rattle has been mainly on the grounds of lower cost, with freedom of central action (undoubtedly beneficial in anaesthesia) proposed as a theoretical benefit.
We undertook our study for the very purpose of confirming that glycopyrrolate was as effective as hyoscine and would save money, before trying to encourage local GP's and hospitals to follow our lead. We stand by our conclusions that our results cast doubt on the costsaving potential, and raise questions over the speed of onset. Further data are obviously needed, but we will continue to use the`old favourite' until the weight of evidence supports change. 
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